Larimar Therapeutics to Present at the SVB Leerink 10th Annual Global Healthcare Conference
BALA CYNWYD, Pa., Feb. 18, 2021 – Larimar Therapeutics (Nasdaq: LRMR) announced that Dr. Carole Ben-Maimon, CEO, will present at the SVB Leerink 10th Annual Global Healthcare Conference from February 22-26, 2021. The presentation is scheduled for February 26, 2021, at 8:00 AM ET, in a fireside chat format. Larimar is a clinical-stage biotech firm focused on therapies for rare diseases, notably evaluating CTI-1601 for Friedreich’s ataxia. More information can be found via their website.
- None.
- None.
BALA CYNWYD, Pa., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon, MD, President and Chief Executive Officer of Larimar Therapeutics, will present and participate in virtual 1x1 investor meetings at the SVB Leerink 10th Annual Global Healthcare Conference taking place virtually from February 22-26, 2021. See below for more details.
| Date: | Friday, February 26, 2021 |
| Time: | 8:00 AM ET |
| Presentation Format: | Fireside chat |
| Webcast link: | https://wsw.com/webcast/svbleerink47/lrmr/2680832 |
About Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program in the U.S. as a potential treatment for Friedreich’s ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.
Forward-Looking Statements
This press release contains forward-looking statements that are based on Larimar’s management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including but not limited to statements regarding Larimar’s ability to develop and commercialize CTI-1601 and other planned product candidates, Larimar’s planned research and development efforts, and other matters regarding Larimar’s business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors include, among others, the success, cost and timing of Larimar’s product development activities, studies and clinical trials; the ongoing impact of the COVID-19 pandemic on Larimar’s clinical trial timelines, ability to raise additional capital and general economic conditions; Larimar’s ability to optimize and scale CTI-1601’s manufacturing process; Larimar’s ability to obtain regulatory approval for CTI-1601 and future product candidates; Larimar’s ability to develop sales and marketing capabilities, whether alone or with potential future collaborators, and successfully commercialize any approved product candidates; Larimar’s ability to raise the necessary capital to conduct its product development activities; and other risks described in the filings made by the Company with the Securities and Exchange Commission (SEC), including but not limited to Larimar’s periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. These forward-looking statements are based on a combination of facts and factors currently known by Larimar and its projections of the future, about which it cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent views as of the date hereof. Larimar undertakes no obligation to update any forward-looking statements for any reason, except as required by law.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
(212) 915-2569
Company Contact:
Michael Celano
Chief Financial Officer
mcelano@larimartx.com
(484) 414-2715
FAQ
When will Larimar Therapeutics present at the SVB Leerink Healthcare Conference?
Who is presenting for Larimar Therapeutics at the conference?
What time is the Larimar Therapeutics presentation?
What is the focus of Larimar Therapeutics?
What is the ticker symbol for Larimar Therapeutics?
What is Larimar's lead compound?
Where can I find more information on Larimar Therapeutics?
